Can-Fite BioPharma Ltd. (TLV:CANF)
Israel · Delayed Price · Currency is ILS · Price in ILA 341.50
-4.80 (-1.39%)
Sep 10, 2026, 5:24 PM IDT
Can-Fite BioPharma Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 2.99 | 5.53 | 4.83 | 4.28 | 2.98 | 4.39 |
Short-Term Investments | 4.06 | 3.01 | 3.06 | 4.64 | 5 | 14.51 |
Trading Asset Securities | - | - | - | - | 0.01 | 0.24 |
Cash & Short-Term Investments | 7.04 | 8.54 | 7.89 | 8.92 | 7.99 | 19.14 |
Cash Growth | 9.09% | 8.28% | -11.60% | 11.71% | -58.27% | 129.40% |
Prepaid Expenses | 0.96 | 0.83 | 1.02 | 0.91 | 1.12 | 0.88 |
Other Current Assets | - | 0.07 | 0.08 | 0.08 | 0.05 | 0.05 |
Total Current Assets | 8 | 9.44 | 8.98 | 9.91 | 9.16 | 20.07 |
Property, Plant & Equipment | 0.05 | 0.07 | 0.14 | 0.08 | 0.13 | 0.19 |
Total Assets | 8.06 | 9.51 | 9.12 | 9.99 | 9.28 | 20.25 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 0.68 | 1.16 | 0.62 | 0.43 | 0.9 | 0.95 |
Accrued Expenses | - | 1.11 | 0.98 | 0.94 | 0.78 | 0.91 |
Current Portion of Leases | 0.05 | 0.06 | 0.05 | 0.03 | 0.05 | 0.05 |
Current Unearned Revenue | 0.41 | 0.41 | 0.41 | 0.62 | 0.78 | 0.82 |
Other Current Liabilities | 1.09 | - | - | - | - | - |
Total Current Liabilities | 2.23 | 2.73 | 2.05 | 2.02 | 2.5 | 2.73 |
Long-Term Leases | 0 | 0.02 | 0.05 | 0.01 | 0.01 | 0.07 |
Long-Term Unearned Revenue | 0.97 | 1.18 | 1.58 | 1.71 | 2.3 | 3.07 |
Total Liabilities | 3.2 | 3.92 | 3.68 | 3.75 | 4.81 | 5.87 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Additional Paid-In Capital | 184.52 | 180.65 | 170.67 | 163.6 | 154.19 | 153.93 |
Retained Earnings | -180.79 | -176.19 | -166.36 | -158.48 | -150.85 | -140.67 |
Comprehensive Income & Other | 1.13 | 1.13 | 1.13 | 1.13 | 1.13 | 1.13 |
Total Common Equity | 4.86 | 5.59 | 5.44 | 6.24 | 4.47 | 14.38 |
Shareholders' Equity | 4.86 | 5.59 | 5.44 | 6.24 | 4.47 | 14.38 |
Total Liabilities & Equity | 8.06 | 9.51 | 9.12 | 9.99 | 9.28 | 20.25 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 0.05 | 0.07 | 0.1 | 0.04 | 0.06 | 0.12 |
Net Cash (Debt) | 6.99 | 8.47 | 7.78 | 8.88 | 7.93 | 19.02 |
Net Cash Growth | 9.87% | 8.81% | -12.37% | 12.08% | -58.32% | 129.76% |
Net Cash Per Share | 2.38 | 5.14 | 10.73 | 20.84 | 29.15 | 103.14 |
Filing Date Shares Outstanding | 4.29 | 4.29 | 1.04 | 0.5 | 0.41 | 0.27 |
Total Common Shares Outstanding | 4.29 | 2.62 | 0.99 | 0.45 | 0.27 | 0.27 |
Working Capital | 5.78 | 6.71 | 6.93 | 7.89 | 6.66 | 17.34 |
Book Value Per Share | 1.13 | 2.14 | 5.47 | 13.77 | 16.45 | 52.89 |
Tangible Book Value | 4.86 | 5.59 | 5.44 | 6.24 | 4.47 | 14.38 |
Tangible Book Value Per Share | 1.13 | 2.14 | 5.47 | 13.77 | 16.45 | 52.89 |
Machinery | - | 0.02 | 0.08 | 0.28 | 0.28 | 0.27 |
Leasehold Improvements | - | - | - | 0.01 | 0.01 | 0.01 |